121 related articles for article (PubMed ID: 21730371)
1. Epigallocatechin gallate inhibits the HIV reverse transcription step.
Li S; Hattori T; Kodama EN
Antivir Chem Chemother; 2011 Jul; 21(6):239-43. PubMed ID: 21730371
[TBL] [Abstract][Full Text] [Related]
2. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
[TBL] [Abstract][Full Text] [Related]
4. Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase.
Mavhandu LG; Cheng H; Bor YC; Tebit DM; Hammarskjold ML; Rekosh D; Bessong PO
J Ethnopharmacol; 2020 Aug; 258():112931. PubMed ID: 32360797
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).
Yamaguchi K; Honda M; Ikigai H; Hara Y; Shimamura T
Antiviral Res; 2002 Jan; 53(1):19-34. PubMed ID: 11684313
[TBL] [Abstract][Full Text] [Related]
6. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
Smith RA; Gottlieb GS; Anderson DJ; Pyrak CL; Preston BD
Antimicrob Agents Chemother; 2008 Jan; 52(1):329-32. PubMed ID: 17967913
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Tachedjian G
Virus Res; 2008 Jun; 134(1-2):147-56. PubMed ID: 18372072
[TBL] [Abstract][Full Text] [Related]
9. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent.
Fassina G; Buffa A; Benelli R; Varnier OE; Noonan DM; Albini A
AIDS; 2002 Apr; 16(6):939-41. PubMed ID: 11919502
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
Pontikis R; Dollé V; Guillaumel J; Dechaux E; Note R; Nguyen CH; Legraverend M; Bisagni E; Aubertin AM; Grierson DS; Monneret C
J Med Chem; 2000 May; 43(10):1927-39. PubMed ID: 10821705
[TBL] [Abstract][Full Text] [Related]
11. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
Shaw-Reid CA; Feuston B; Munshi V; Getty K; Krueger J; Hazuda DJ; Parniak MA; Miller MD; Lewis D
Biochemistry; 2005 Feb; 44(5):1595-606. PubMed ID: 15683243
[TBL] [Abstract][Full Text] [Related]
13. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
14. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
Okamoto M; Makino M; Yamada K; Nakade K; Yuasa S; Baba M
Antiviral Res; 1996 Jun; 31(1-2):69-77. PubMed ID: 8793010
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-HIV-1 activity of 1-substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils.
Loksha YM; Pedersen EB; Loddo R; La Colla P
Arch Pharm (Weinheim); 2009 Sep; 342(9):501-6. PubMed ID: 19637180
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
Williamson MP; McCormick TG; Nance CL; Shearer WT
J Allergy Clin Immunol; 2006 Dec; 118(6):1369-74. PubMed ID: 17157668
[TBL] [Abstract][Full Text] [Related]
18. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
19. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
